ELI LILLY & Co - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 8, 2024, serves as a current report for Eli Lilly and Company. The filing primarily references a press release (Exhibit 99.1) announcing financial results for the quarter ended June 30, 2024.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) which is incorporated by reference but not included in the text of this 8-K.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It directs readers to the attached press release for the announcement of financial results for the quarter ended June 30, 2024.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the body of this 8-K. The document states that the information in Item 2.02 is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act, except as expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2024) for specific Q2 2024 revenue and earnings figures.
- Verify the specific details of the financial results and any updated guidance provided in the press release.
- Confirm the status of the company's various registered debt securities listed in the filing (e.g., Notes due 2025, 2026, 2030, etc.).
- Note that the financial data in this 8-K is furnished and not subject to the liabilities of Section 18 of the Exchange Act.